common.study.topics.clinical

Suvorexant and Cocaine

common.study.values.description

Suvorexant and Cocaine

The research proposed here will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for cocaine, as well as other cocaine-associated maladaptive behaviors in active cocaine users. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of cocaine in humans. As such the outcomes will contribute to our understanding of the clinical neurobiology of cocaine use disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on cocaine addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Suvorexant

The pharmacodynamic effects of suvorexant maintenance will be determined.

Drug - Cocaine

The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.

Drug - Placebo oral capsule

The pharmacodynamic effects of placebo will be determined.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Influence of Orexin Antagonism on Motivation for Cocaine

common.study.values.clinical-trial-id

NCT03937986

participant.views.study.view.id

bqx9ya